Metabolic Signaling
GLP-2T Dual Agonist
Dual GIP/GLP-1 receptor agonist
Dual GIP / GLP-1 Receptor Agonist
Research context
This compound is a 39-residue synthetic peptide derived from the GIP sequence, engineered for activity at both the GIP and GLP-1 receptors with reported imbalance favouring GIP. Research examines relative receptor potency, β-arrestin recruitment profiles, and biased agonism at each receptor.
Common assays: GIPR/GLP-1R dual binding · cAMP accumulation · β-arrestin recruitment · Receptor internalisation
Specification
| Designation | Dual GIP/GLP-1 receptor agonist |
|---|---|
| Full name | Dual GIP / GLP-1 Receptor Agonist |
| Sequence | Synthetic 39-residue peptide based on the GIP sequence with Aib substitutions |
| CAS number | 2023788-19-2 |
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813.45 g/mol |
| Formats | 10 mL Vial · 15 mL Advanced Liquid Peptide Spray |
| Solubility | Bacteriostatic water, sterile water |
| Storage | Lyophilised: 2–8 °C, protected from light. Reconstituted: 2–8 °C. |
| Current lot | TIR40N1125 → |
GLP-2T Dual Agonist COA: certificates of analysis by lot
4 lots of GLP-2T Dual Agonist have a published certificate of analysis from AxisPharm, LLC, an independent laboratory. Each certificate reports the laboratory's results for that lot.
| Lot | Format | Purity (HPLC-UV) | Reported |
|---|---|---|---|
| TIR40N1125 | 40 mg Spray | >99.0% | 2025-11-24 |
| TIR40V1125 | 40 mg Vial | >99.0% | 2025-11-13 |
| TIR20N1125B | 20 mg Spray | >99.0% | 2025-11-13 |
| TIR10V1125 | 10 mg Vial | >99.0% | 2025-11-13 |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Coskun T, Sloop KW, Loghin C, et al.LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of conceptMolecular Metabolism · 2018 Find on PubMed ↗
- Willard FS, Douros JD, Gabe MB, et al.Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistJCI Insight · 2020 Find on PubMed ↗
Common questions
What makes this a dual agonist?
It is based on the GIP sequence but engineered to also activate the GLP-1 receptor. Published characterisation reports differing potency at the two receptors rather than balanced activity.
What is biased agonism in the dual-agonist literature?
It refers to a ligand preferentially activating one downstream pathway over another at the same receptor — here, reported differences between cAMP signalling and β-arrestin recruitment at GLP-1R.
Where can I see the GLP-2T Dual Agonist certificate of analysis?
Every published GLP-2T Dual Agonist lot has its own certificate page on this site, listed under "GLP-2T Dual Agonist COA" above. There are 4 published lots; the most recent, lot TIR40N1125, was reported on 2025-11-24 at >99.0% purity by HPLC-UV. The certificates are issued by AxisPharm, LLC, an independent laboratory.
Components, blends and pathway
Related compounds
GLP-1S
GLP-1 receptor agonist
A long-acting glucagon-like peptide-1 receptor agonist studied in incretin signalling research.
GLP-3R Triple Agonist
Triple GLP-1/GIP/glucagon receptor agonist
A synthetic triple agonist at GLP-1, GIP and glucagon receptors, studied in multi-receptor incretin research.
GLP-3R / GLP-1S Agonist Blend
Dual agonist blend
A prepared blend combining a triple receptor agonist and a GLP-1 receptor agonist in a single metered format.
AOD-9604
HGH Fragment 176-191
A modified C-terminal fragment of human growth hormone studied in lipid metabolism research.